Terms: = Skin cancer AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Treatment
30 results:
1. Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells.
Saamarthy K; Ahlqvist K; Daams R; Balagunaseelan N; Rinaldo-Matthis A; Kazi JU; Sime W; Massoumi R
BMC Cancer; 2024 Jan; 24(1):103. PubMed ID: 38238702
[TBL] [Abstract] [Full Text] [Related]
2. Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid Tumors.
Liu Y; Mullangi S; Debono D; Chen X; Pham T; Fisch MJ; Gordon AS; Hershman DL
JCO Oncol Pract; 2023 Sep; 19(9):731-740. PubMed ID: 37384847
[TBL] [Abstract] [Full Text] [Related]
3. Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial.
Meduri B; Baldissera A; Iotti C; Scheijmans LJEE; Stam MR; Parisi S; Boersma LJ; Ammendolia I; Koiter E; Valli M; Scandolaro L; Busz D; Stenfert Kroese MC; Ciabatti S; Giacobazzi P; Ruggieri MP; Engelen A; Munafò T; Westenberg AH; Verhoeven K; Vicini R; D'Amico R; Lohr F; Bertoni F; Poortmans P; Frezza GP
J Clin Oncol; 2023 Apr; 41(12):2201-2210. PubMed ID: 36623246
[TBL] [Abstract] [Full Text] [Related]
4. Investigation of radiomics based intra-patient inter-tumor heterogeneity and the impact of tumor subsampling strategies.
Henry T; Sun R; Lerousseau M; Estienne T; Robert C; Besse B; Robert C; Paragios N; Deutsch E
Sci Rep; 2022 Oct; 12(1):17244. PubMed ID: 36241749
[TBL] [Abstract] [Full Text] [Related]
5. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.
Tang K; Seo J; Tiu BC; Le TK; Pahalyants V; Raval NS; Ugwu-Dike PO; Zubiri L; Naranbhai V; Carrington M; Gusev A; Reynolds KL; LeBoeuf NR; Asgari MM; Kwatra SG; Semenov YR
JAMA Dermatol; 2022 Feb; 158(2):189-193. PubMed ID: 35019948
[TBL] [Abstract] [Full Text] [Related]
6. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases.
Ismail RK; Sikkes NO; Wouters MWJM; Hilarius DL; Pasmooij AMG; van den Eertwegh AJM; Aarts MJB; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije BJ; van der Veldt AAM; Vreugdenhil A; van Dartel M; de Boer A
Melanoma Res; 2021 Feb; 31(1):58-66. PubMed ID: 33351553
[TBL] [Abstract] [Full Text] [Related]
7. The genus Schefflera: A review of traditional uses, phytochemistry and pharmacology.
Wang Y; Khan FA; Siddiqui M; Aamer M; Lu C; Atta-Ur-Rahman ; Atia-Tul-Wahab ; Choudhary MI
J Ethnopharmacol; 2021 Oct; 279():113675. PubMed ID: 33301919
[TBL] [Abstract] [Full Text] [Related]
8. Correlation study between the magnetic resonance imaging features of breast cancer and expression of immune molecular subtypes.
Long N; Ran C; Sun J; Hao CJ; Sui YB; Li J; Shi YX; Zou ZX; Qu YH
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11518-11527. PubMed ID: 33275218
[TBL] [Abstract] [Full Text] [Related]
9. Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell Carcinoma.
Butala AA; Jain V; Reddy VK; Sebro RA; Song Y; Karakousis G; Mitchell TC; Lukens JN; Shabason JE
Oncologist; 2021 Jan; 26(1):63-69. PubMed ID: 32886418
[TBL] [Abstract] [Full Text] [Related]
10. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract] [Full Text] [Related]
11. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
Esse S; Mason KJ; Green AC; Warren RB
JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
[TBL] [Abstract] [Full Text] [Related]
13. Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States.
Amini A; Rusthoven CG; Waxweiler TV; Jones BL; Fisher CM; Karam SD; Raben D
J Am Acad Dermatol; 2016 Feb; 74(2):309-16. PubMed ID: 26670715
[TBL] [Abstract] [Full Text] [Related]
14. Expression and clinicopathological significance of microRNA-21 and programmed cell death 4 in malignant melanoma.
Jiao J; Fan Y; Zhang Y
J Int Med Res; 2015 Oct; 43(5):672-8. PubMed ID: 26150475
[TBL] [Abstract] [Full Text] [Related]
15. Cluster analysis of multiplex ligation-dependent probe amplification data in choroidal melanoma.
Caines R; Eleuteri A; Kalirai H; Fisher AC; Heimann H; Damato BE; Coupland SE; Taktak AF
Mol Vis; 2015; 21():1-11. PubMed ID: 25684974
[TBL] [Abstract] [Full Text] [Related]
16. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG
Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy of manual lymphatic drainage and intermittent pneumatic compression pump use in the treatment of lymphedema after mastectomy: a randomized controlled trial.
Uzkeser H; Karatay S; Erdemci B; Koc M; Senel K
Breast Cancer; 2015 May; 22(3):300-7. PubMed ID: 23925581
[TBL] [Abstract] [Full Text] [Related]
18. CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways.
Ke H; Augustine CK; Gandham VD; Jin JY; Tyler DS; Akiyama SK; Hall RP; Zhang JY
J Invest Dermatol; 2013 Jan; 133(1):221-9. PubMed ID: 22832488
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract] [Full Text] [Related]
20. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.
Hwang JH; Lim MC; Seo SS; Park SY; Kang S
Jpn J Clin Oncol; 2011 May; 41(5):624-9. PubMed ID: 21355002
[TBL] [Abstract] [Full Text] [Related]
[Next]
